sabato, 25 marzo 2023
9 Novembre 2018

FDA Approves Elotuzumab Triplet for Myeloma

November 6, 2018 – The FDA has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor (PI). The approval was based on the phase II ELOQUENT-3 trial, in which the addition of elotuzumab to pomalidomide and dexamethasone reduced the risk of disease … (leggi tutto)